Name | 1-butylbiguanide |
Synonyms | DBV Buformin Butformin Buformine Butylbiguanide Butyldiguanide 1-butylbiguanide N-BUTYLBIGUANIDINE |
CAS | 692-13-7 |
EINECS | 2117264 |
Molecular Formula | C6H15N5 |
Molar Mass | 157.2168 |
Density | 1.0291 (rough estimate) |
Boling Point | 271.89°C (rough estimate) |
Refractive Index | 1.8070 (estimate) |
Biological activity | Buformin (1-Butylbiguanide) is an effective AMPK activator and a biguanide hypoglycemic agent with oral activity (antidiabetic agent). Buformin reduces hepatic gluconeogenesis and blood sugar production. Buformin also has anti-cancer activity and can be applied to cancer research, such as cervical cancer, breast cancer, etc. |
Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells ErbB-2-overexpressing SKBR3 and BT474 cells ErbB-2-overexpressing SKBR3 and BT474 cells |
Concentration: | 0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300μM, 1, 3, or 10mM 0.5 mM; 1 mM; 3 mM 0mM, 0.1mM, 0.3mM, 1mM, or 3mM |
Incubation Time: | 5 days 48 hours 24 hours |
Result: | Reduced cell viability in erbB-2-overexpressing breast cells. Increased cells arresting in G0/G1 phase. Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner. Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice. |
Animal Model: | Female MMTV-erbB-2 transgenic mice |
Dosage: | 7.6mmol/kg |
Administration: | Oral administation; 7 days |
category | toxic substances |
toxicity classification | highly toxic |
acute toxicity | oral administration-mouse LD50: 300 mg/kg; Abdominal cavity-mouse LD50: 140 mg/kg |
flammability hazard characteristics | thermal decomposition discharges toxic nitrogen oxide smoke |
storage and transportation characteristics | warehouse ventilation and low temperature drying; separate from food raw materials |
fire extinguishing agent | water, dry powder, carbon dioxide, foam |